Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Glioblastoma 4Brain Neoplasms 4Neuroblastoma 3Recurrence 2Neoplasms 2Melanoma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Hodgkin Disease 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Gliosarcoma 1Disease Progression 1Central Nervous System Neoplasms 1Breast Neoplasms 1

Interventions

Rituximab 344Cyclophosphamide 317fludarabine phosphate 142Etoposide 139Peripheral Blood Stem Cell Transplantation 124fludarabine 112Filgrastim 112Mycophenolic Acid 98Melphalan 98Whole-Body Irradiation 90Vincristine 90Busulfan 87Cytarabine 85Doxorubicin 79Cyclosporine 76Tacrolimus 75Radiotherapy 75Prednisone 73Bendamustine Hydrochloride 72Granulocyte Colony-Stimulating Factor 66Methotrexate 65Antilymphocyte Serum 56Carmustine 54Dexamethasone 50Gemcitabine 48Lenalidomide 46Bortezomib 43venetoclax 41ibritumomab tiuxetan 37obinutuzumab 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, Non-Hodgkin × TPI-287 × Clear all
NCT00113724 2009-06-04

Study of TPI 287 in Patients With Advanced Malignancies

Cortice Biosciences, Inc.

Phase 1 Completed
48 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasms

NCT00256191 2007-10-15

Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies

Cortice Biosciences, Inc.

Phase 1 Completed
45 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡